A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib

Lung cancer is the leading cause of death for cancer worldwide.1 From a histological point of view, non-small cell lung cancer (NSCLC) represents the vast majority (about 85%) of cases.2 As a general rule, a high percentage of patients were diagnosed in advanced stages (IIIB/C-IV). In the past, for advanced stage NSCLC patients the only therapeutic choice was represented by chemotherapy. Currently, technological and therapeutic developments, with the introduction of tyrosine kinase inhibitors (TKIs) and immunotherapy, have led to a significant improvement in the survival outcomes of these patients.